Epic Sciences launches metastatic breast cancer circulating tumor cell panel.
Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for characterization of circulating tumor cells (CTCs) within a blood sample.
Multiple biopharma and academic institutes are actively utilizing the panel as a clinical research tool to analyze the impact of dozens of novel and standard of care therapies in context to biochemical drivers of disease progression.
“The biochemical complexity and inherent tumor heterogeneity of metastatic breast cancer requires more comprehensive and precise analysis than what has been thus far available to cancer researchers,” said Mark Landers, vice president of translational research at Epic Sciences. “The ability to characterize the active metastatic portion of a patient’s tumor burden from a liquid biopsy with single cell resolution in the context of tumor heterogeneity is a major advancement in understanding breast cancer disease progression and will significantly aid the development of novel therapeutics.”
In addition to measuring changes in circulating tumor burden, the panel assays clinically relevant hormone receptor status, genomic drivers, and novel morphologic signatures for homologous recombination deficiency (HRD) and heterogeneity on every CTC individually. These biomarkers cover a large portion of therapeutic classes currently employed in clinical trials. The panel design enables flexibility of analysis based upon the needs of the clinical research being employed.
“Utilizing the Epic breast cancer panel, we have uncovered sub-clonal drivers of disease progression not found through tissue or ctDNA analysis,” said Landers. “These insights are already enabling investigators to improve clinical trial design and find novel therapeutic strategies for patients with metastatic breast cancer.”
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org,+1.858.344.8091